Browsing by Subject "cyclophosphamide"
Now showing items 21-28 of 28
-
The risk of lymphoma development in autoimmune diseases: A meta-analysis
(2005)Background: The risk of development of non-Hodgkin lymphoma (NHL) in autoimmune patients has been investigated in several cohort studies. These studies revealed inconclusive results. To shed some light on this controversy, ... -
Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab
(2011)Background: Although renal involvement in advanced haematological malignancies is common, glomerulonephritis associated with lymphoproliferative disorders is rare, and the related pathogenetic mechanisms are still poorly ... -
A systematic review and meta-analysis of pharmacogenetic studies in patients with chronic kidney disease
(2021)Chronic kidney disease (CKD) is an important global public health problem due to its high prevalence and morbidity. Although the treatment of nephrology patients has changed considerably, ineffectiveness and side effects ... -
Systemic sclerosis: From pathogenesis towards targeted immunotherapies
(2012)Systemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur ... -
Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: A pooled analysis of randomized controlled trias by the hellenic academy of oncology
(2019)Background: Adjuvant chemotherapy has an indisputable value for early breast cancer patients. Anthracycline and taxane-based regimens (TaxAC) have not been proven superior to taxane & cyclophosphamide (TC), a less toxic ... -
Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
(2020)Background: European data indicate that systemic sclerosis (SSc)-related death rates are increasing, thus raising concerns about SSc's optimal management. Herein, we describe current treatment modalities and drug survival ... -
Treatment of lung cancer
(2012) -
Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus
(2008)Objective. We have observed several cases of patients with systemic lupus erythematosus (SLE) who developed antiphospholipid antibodies (aPL) or full blown antiphospholipid syndrome (APS) after being successfully treated ...